---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-038258"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2026-08-14T19:20:31+00:00"
generated_at: "2026-08-14T19:23:04.894357+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics Q2 net loss widens to $5.2M; raises going-concern doubt

## Summary
- Q2 2026 net loss $5.2M vs $1.9M YoY; six-month loss $1.7M vs $4.1M; revenue $135.6K vs $6.6K.
- HCW9302 Phase 1: all 3 patients in 3 µg/kg cohort showed ≥25% SALT score reduction; no dose-limiting toxicities; full readout Q4 2026.
- Re-acquired ex vivo rights to HCW9206 from AlloTera; pursuing partner for CAR-T reagent market.
- Raised $5.6M in May/July private placements; officers/directors participated.
- Company expresses substantial doubt about going concern for next 12 months; Nasdaq compliance regained but monitor possible.

## SEC filing metadata
- accession: 0001493152-26-038258
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2026-08-14T19:20:31+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000149315226038258/0001493152-26-038258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000149315226038258/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-038258
- JSON: https://secwatch.observer/filing/0001493152-26-038258.json
- Plain text: https://secwatch.observer/filing/0001493152-26-038258.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.